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INTRODUCTION
The epidermal barrier prevents transepidermal water loss, essential for
ex-utero survival. To this end mammalian fetuses acquire barrier
function late in gestation (Hardman et al., 1998; Hardman et al., 1999).
Formation of the murine epidermal barrier is rapid. Between
embryonic day 16.5 (E16.5) and E17.5 a wave of epidermal barrier
formation sweeps across murine fetal skin to converge on ventral and
dorsal midlines. Barrier formation can be visualized by dye
permeability assays (Hardman et al., 1998; Hardman et al., 1999) (see
also Fig. 1; timing is strain dependent; see Materials and methods).
The serine/threonine kinase Akt changes expression and activity
during fetal barrier acquisition (O’Shaughnessy et al., 2007b) (Fig.
1), and Akt activity is essential for barrier formation. Mice lacking
both Akt1 and Akt2 die postnatally, probably due to lack of
epidermal barrier function (Peng et al., 2003). However, although
Akt1 nulls have defective cornified envelopes (O’Shaughnessy et al.,
2007b), both Akt1 and Akt2 knockouts are viable, suggesting a
degree of redundancy between these Akt proteins. Phosphorylated
active Akt is found in two regions of the epidermis – the lower
suprabasal epidermis and the upper granular layer (Janes et al., 2004;
O’Shaughnessy et al., 2007b). Our previous work has determined
that this lower suprabasal activity mostly comprises Akt2, whereas
the upper granular layer activity mostly comprises Akt1
(O’Shaughnessy et al., 2007a; O’Shaughnessy et al., 2007b).
Akt activity is also present in cultured keratinocytes, probably
corresponding to the lower suprabasal activity (Janes et al., 2004;
Calautti et al., 2005; Thrash et al., 2006; O’Shaughnessy et al.,
2007b). Multiple roles have been proposed for epidermal Akt, from
the initiation of the terminal differentiation program (Janes et al.,
2004; Calautti et al., 2005; Thrash et al., 2006; O’Shaughnessy et
al., 2007b; Janes et al., 2009) to the correct formation of the
cornified envelope during late terminal differentiation, partly by
regulating filaggrin processing (O’Shaughnessy et al., 2007a;
O’Shaughnessy et al., 2007b).
In vivo, lower suprabasal Akt activity peaks around E17 with
expression diminishing around E18, which encompasses the period
of barrier acquisition in the mouse embryo (O’Shaughnessy et al.,
2007b). However, the relationship between Akt function and
developmental barrier acquisition remains to be ascertained. To
investigate the relationship between embryonic epidermal
development and the initial acquisition of epidermal barrier function
we used an approach that co-visualizes protein expression and
barrier function.
We found that that there was a ‘pulse’ of high Akt activity
coincident with the barrier acquisition front. Dephosphorylation of
Jun (also known as c-jun) also coincided with barrier acquisition and
was prevented by inhibition of either Akt or protein phosphatase 2A
(Pp2a). We show that expression of the Pp2a regulatory subunit
Ppp2r2a, also known as B55α or Pr55α, was Akt-dependent, and
that in organotypic culture reducing Ppp2r2a expression resulted in
maintenance of Jun phosphorylation and a transient barrier defect,
followed by hyperkeratosis. In this paper we present evidence that a
novel Akt-mediated Pp2a function, acting via Jun signaling, is
necessary for epidermal barrier function.
MATERIALS AND METHODS
General immunohistochemistry and immunofluorescence
Immunohistochemistry on paraffin and frozen sections was by standard
techniques. Keratinocytes were fixed for 10 minutes at 4°C in 4%
paraformaldehyde in phosphate buffered saline (PBS), then permeabilized
in 0.2% Triton X-100 (Sigma, Gillingham, UK) for 30 minutes. Antibodies
used were as follows: rabbit anti pSer473 Akt (Cell Signaling Technologies,
Danvers, USA) 1/10; rabbit anti Keratin 10 (Covance, Cambridge, UK)
1/500; rabbit anti-filaggrin (Covance) 1/500; rabbit anti-loricrin (Covance)
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1/500; rabbit anti-Jun (Cell Signaling Technologies) 1/10; rabbit anti-pSer63
Jun (Cell Signaling Technologies) 1/10; rabbit anti-pSer2448 mTOR 1/50
(Cell Signaling Technologies); sheep anti-PPP2R2A (Abcam, Cambridge,
UK) 1/25; mouse anti-PP2AC (BD Biosciences, Dendermonde, Belgium)
1/50; goat anti-GKLF (KLF4) (Santa Cruz Biotechnologies, Santa Cruz,
US) 1/20. Antibody detection was by either the Elite Avidin-Biotin-
Complex system and DAB (Vector Laboratories, Burlingame, USA) or
Alexa Fluor 488 (green) and 536 (red)-conjugated secondary antibodies
(Molecular Probes). Counterstaining was with Hematoxylin for
immunohistochemistry and 4,6-diamidino-2-phenylindole (DAPI) for
immunofluorescence. Images were taken with a Nikon Eclipse E600
microscope with either 20 (NA 0.4) or 60 oil immersion (NA 1.40)
objectives, using a SPOT digital camera (Diagnostic Instruments Inc.,
Sterling Heights, USA) with Spot RT Software v3.0.
Barrier assays, selection of skin samples flanking the barrier front
and co-visualization of barrier activity and protein abundance
The Toluidine Blue barrier assay (dye permeability assay, dye exclusion
assay) was performed on E16.5 CD1 embryos or embryonic epidermal
explants fixed in 4% paraformaldehyde in PBS as described (Hardman et
al., 1998); note that barrier formation will occur later, approximately
E17.5, in other strains of mouse, e.g. C57BL/6. Briefly, fixed embryos or
tissues were dehydrated with methanol (approximately 1 minute each in
25, 50, 75 and then 100% ethanol) then rehydrated using the reverse
procedure, followed by immersion in 1% Toluidine Blue in water, then
extensive destaining in PBS.
For selection of epidermal samples flanking the barrier front, we took
mouse embryos at E16.5, removed a strip of epidermis from the middle of
the body and cut it in half longitudinally. We fixed and stained one half in
Toluidine Blue. Lining this up with the adjacent strip allowed us to obtain
skin that was crudely pre-barrier formation and post-barrier formation (Fig.
1B). Alternatively, the barrier front was marked by an incision.
For visualizing protein and barrier competence simultaneously, and for
visualizing barrier function in organotypic culture, fixed and dehydrated/
rehydrated embryos or cultures were dipped for one minute in 1%
Hematoxylin in water and washed several times before embedding in
paraffin. Subsequent immunohistochemistry was by standard techniques.
Embyronic epidermal explant culture
Explant culture of murine late embryonic skin has been described previously
(O’Shaughnessy et al., 2007a). Briefly, skin (epidermis plus dermis) was
dissected from the torso region of E15.5 CD1 mice, rinsed in sterile PBS and
cultured dermis side down, at the air-liquid interface for 48 hours, covering
the period of barrier formation. Explants were cultured in Williams Medium
E supplemented with 10 μg/ml insulin, 10 ng/ml hydrocortisone, 2 mM
glutamine, 100 IU/l penicillin, 100 mg/l streptomycin and 25 μg/ml
amphotericin (all reagents from Invitrogen, Paisley, UK). For the inhibitor
experiments, SH-5 (100 μM; Enzo Life Sciences, Exeter, UK), okadaic acid
(10 nM; Sigma), Fostriecin (20 μm; Sigma) and fenvalerate (20 μM; Sigma)
in DMSO (Sigma) were added to the medium before culture. Explants were
fixed in Bouin’s solution (Sigma) for 2 hours before processing for paraffin
embedding, or embedded in OCT for cryosectioning.
siRNA constructs, rat epidermal keratinocyte culture and
organotypic culture
The SureSilencing shRNA plasmids to rat PPP2R2A (insert sequences
siRNA1-GCAGATGATTTGCGAATTAAT, siRNA2-TGACTGGAT CC -
TACAATAATT in pSuperNeo) were from Tebo-bio (Peterborough, UK).
Constructs were transfected into transformed rat epidermal keratinocytes
(REK) (Marjukka et al., 2003) cells using lipofectamine plus (Invitrogen,
Paisley, UK). Selection in 100 μM G418 (Invitrogen, Paisley, UK) was
undertaken for 2 weeks. REK cells were passaged in DMEM +10% fetal calf
serum. For immunofluorescence analysis, the cells were subsequently
simultaneously fixed and permeabilized in 4% paraformaldehyde/0.2%
Triton X-100. Organotypic culture was performed as described by
O’Shaughnessy et al. (O’Shaughnessy et al., 2007b), briefly, 2105 rat
epidermal keratinocytes were cultured in medium containing 100 mg/ml
G418 on de-epidermized dermis made from cadaverous skin (Euro Skin
Bank, Beverwijk, Netherlands) in a metal ring until confluent. Subsequently
the organotypic cultures were raised to the air-liquid interface and cultured
for a further 10 days, unless specified. When used in organotypic culture,
SP600125 (Sigma), a Jun kinase inhibitor, was added to the medium at 50
nM. The constructs were processed for paraffin embedding by fixing in
Bouin’s solution (Sigma) or 4% paraformaldehyde before the Hematoxylin
barrier assay.
Western blot analyses
Keratinocytes were lysed by incubation on ice for 10 minutes in NP-40 lysis
buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM PMSF, 1 mM EDTA,
5 μg/ml aprotinin, 5 μg/ml leupeptin, 1% Nonidet-40). Immunoprecipitation
of the lysate was performed with 1 μg of either a total Jun antibody (Abcam)
or Ppp2r2a antibody (Abcam), and the complexes were pulled down using
protein A conjugated to agarose (Sigma).
Lysates were separated on 7.5-10% SDS/polyacrylamide gels and
transferred onto nitrocelluose filters (Hybond C+–Amersham). Primary
antibodies and concentrations were as follows: rabbit anti-pSer473 (Cell
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Fig. 1. Akt signaling and Jun dephosphorylation at the barrier front. (A) Typical Toluidine Blue dye penetration (permeability) assay to assess
barrier in an E16.5 mouse embryo. The barrier has progressed half way around the animal. The strip indicates the region assessed for protein
expression. V, ventral; D, dorsal. (B) Assessment of Akt expression and activity (pAkt) by western blots of lysates from an epidermal strip comprising
the barrier front (top panel). (C) Immunohistochemical detection of active Akt (pAkt), keratin 10, filaggrin, phosphorylated Jun (pJun), Jun and Klf4
in skin sections flanking the barrier front. Arrowheads point to expression of Jun and pJun in the upper granular layer. Dashed lines indicate the
dermal-epidermal junction. Scale bar: 50μm. D
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Signaling Technologies) 1/500; rabbit anti-total Akt (Cell Signaling
Technologies) 1/1000; mouse anti-beta actin (Sigma) 1/2000; sheep anti-
PPP2R2A (Abcam) 1/500; rabbit anti-Jun (Abcam) 1/100. Primary
antibody incubations were in TBST [100 mM Tris HCl, 0.2 M NaCl,
0.1% Tween-20 (v/v)] containing 5% bovine serum albumin (Sigma)
either overnight at 4°C or for 1-2 hours at room temperature, whereas
secondary antibody incubations were in 5% skimmed milk powder for 1
hour at room temperature. The following concentrations were used: goat
anti-rabbit-HRP (Jackson ImmunoResearch) 1:5000; rabbit anti-mouse
HRP (DakoCytomation) 1:2000; donkey anti-goat (Jackson
ImmunoResearch) 1:3000. Protein was visualized using the ECL Plus kit
(Amersham).
RESULTS
Akt signaling increases and pJun expression falls
during barrier formation
The formation of the epidermal barrier in the embryonic mouse can
be visualized by dye permeability assays (Fig. 1A) (Hardman et al.,
1998). We used these assays to select skin samples flanking the
barrier formation front (Fig. 1B, see Materials and methods) and
examined the expression of total Akt and active Akt, as determined
by phosphorylation at serine 473 (pAkt). Total levels of Akt were
unchanged during barrier formation, but there was an increase in
pAkt (Fig. 1B), showing that Akt activity increased at this crucial
point in late epidermal development.
Immunohistochemistry was performed on E16.5 embryonic
skin samples flanking the barrier front (Fig. 1C). Consistent with
the western data, there was increased expression of pAkt in the
lower suprabasal region of the epidermis in the sample taken after
barrier acquisition. This must represent the initiation of the pulse
of suprabasal Akt activity associated with Akt2 previously
reported in late gestation murine skin (O’Shaughnessy et al.,
2007b). There was no change in the epidermal differentiation
markers keratin 10 or filaggrin. The expression of the
transcription factor Klf4, which is strongly implicated in the
formation of the cornified layer (Segre et al., 1999), was present
both post- and pre-barrier acquisition, suggesting that this
important transcription factor does not play a role at this stage of
barrier acquisition, although it clearly has a role in the
developmental program that leads to cornified layer formation.
Like pAkt, Jun has been reported in two regions of adult
epidermis: in the lower suprabasal layer and in the uppermost
granular layer (Mehic et al., 2005; Zenz et al., 2005). We found
both unphosphorylated Jun (Jun) and phosphorylated active Jun
[pJun, Ser63 phosphorylation (Binetruy et al., 1991; Smeal et al.,
1991)] in the basal/lower suprabasal and upper granular layers
(the arrowheads in Fig. 1C show the granular layer – note this
flattened layer contains fewer nuclei) of embryonic epidermis
before barrier formation (Fig. 1C). However, after barrier
formation phosphorylation of Jun at Ser63 was undetectable,
whereas Jun expression was maintained. These data suggest that
during barrier formation, signaling via Jun is deactivated, possibly
by phosphatase activity (Fig. 1C).
The dephosphorylation of Jun is transient during epidermal
development, with phosphorylation being restored by E18.5 (Fig. 2)
and maintained in adult epidermis (data not shown). This dynamic
pattern of Jun dephosphorylation associated with the barrier front
resembles the pulse of high suprabasal Akt activity in the vicinity of
the barrier front (Fig. 1B,C; Fig. 2, compare E17.5 panels)
(O’Shaughnessy et al., 2007b).
Co-visualization of barrier formation and protein
expression shows a pulse of Akt activity at the
barrier front co-incident with Jun
dephosphorylation
To examine precisely the dynamics of Akt and Jun
phosphorylation as barrier formed, a modification of the standard
barrier assay was used (see Materials and methods) whereby the
permanent histological dye Hematoxylin was used instead of
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Fig. 2. Reduced Jun phosphorylation correlates with suprabasal Akt activity during development. Immunohistochemical analysis of pAkt,
pJun and Jun in E15.5-19.5 dorsal mouse skin. pAkt expression increases from E16.5 in the lower suprabasal epidermis but is lost by E18.5. Upper
granular layer pAkt expression starts at E17.5 and persists. Jun expression is maintained throughout the developmental series; however, pJun
expression is markedly reduced in E17.5 epidermis. Arrowheads indicate examples of nuclear expression of pJun and Jun in the granular layer. The
dashed lines indicate the dermal-epidermal junction. Scale bar: 50μm. D
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Toluidine Blue. Hematoxylin penetrates the embryos and stains
the nuclei in the absence of barrier, and this staining persists
through tissue embedding and preparation of sections for
immunohistochemistry (Fig. 3A,B). Phosphorylated Jun
disappeared after the barrier front passed (Fig. 3A, compare insets
1 and 2 with inset 3). The phosphorylation of Akt in lower
suprabasal keratinocytes began before the formation of barrier
(barrier front shown with an arrowhead in Fig. 3B) with activity
diminishing after the barrier front had passed (Fig. 3B, compare
insets 1 and 2 with inset 3). These data show precise coincidence
of the pulse of suprabasal Akt activation with barrier formation,
overlapping and slightly preceding the pulse of Jun
dephosphorylation.
Jun is dephosphorylated in keratinocytes during
barrier formation by an Akt-dependent
mechanism
Explant cultures from developing late embryonic mouse skin
recapitulate in vivo development and after 2 days in culture form
a bone fide differentiated epidermis comparable with E17.5
epidermis with barrier function (O’Shaughnessy et al., 2007a).
Akt activity, measured by expression of pAkt, is present in both
the lower suprabasal epidermis and the upper granular layer. This
experimental system was used to modulate Akt activity using the
SH-5 phosphatidyl inositol analog, shown to be a highly specific
inhibitor for Akt (Kozikowski et al., 2003). Treatment with SH-5
caused a reduction in pAkt expression in explants detectable by
immunohistochemistry (Fig. 4A) and by western blot (see Fig. S1
in the supplementary material). SH5 treatment caused inhibition
of stratum corneum formation, compared with DMSO controls
(Fig. 4A), consistent with previous reports of epidermal Akt
inhibition (Peng et al., 2003; O’Shaughnessy et al., 2007b).
Loricrin expression was unchanged, suggesting that the overall
program of epidermal terminal differentiation was unaltered.
Treatment with SH-5 reduced epidermal pAkt levels and reduced
the expression of phosphorylated mTOR, a known downstream
target of Akt (Levine et al., 2006), validating the experimental
approach. Toluidine Blue barrier permeability assays on the
explant cultures showed that Akt inhibition by SH-5 had
qualitatively impaired barrier formation (Fig. 4B), another known
consequence of inhibiting Akt signaling during development
(Peng et al., 2003; O’Shaughnessy et al., 2007a).
SH-5 treated explants failed to downregulate the phosphorylation
of Jun (Fig. 4A), which occurred in the DMSO-treated explant
controls with intact Akt signaling and is expected developmentally
(Figs 1-3). Abundant unphosphorylated Jun was detectable after
both treatments. Therefore, taken together we can deduce that
dephosphorylation of Jun during barrier formation is likely to be by
an Akt-dependent mechanism.
Dephosphorylation of Jun and formation of
epidermal barrier function are mediated by a
Pp2a phosphatase
Pp2a is a serine threonine protein phosphatase that is known to play
an important role in epidermal differentiation, including the
dephosphorylation of filaggrin (Kam et al., 1993). As Pp2a can also
downregulate the activity of the Jun N-terminal kinase (JNK)
(Shanley et al., 2001), we chose this phosphatase for further
investigation.
Late embryonic skin explants were treated with the Pp2a
inhibitors okadaic acid and Fostriecin to determine whether the
dephosphorylation of Jun in epidermis was mediated by a member
of the Pp2a family, and whether the inhibition of Pp2a led to an
epidermal barrier defect (Fig. 5). Fostriecin was included as it has
greater specificity for Pp2a than okadaic acid. Fenvalerate was used
as a second control, as it inhibits the Pp2b family phosphatases.
In both the okadaic acid- and Fostriecin-treated explants there
was maintenance of phosphorylation of Jun, which was not
observed in the fenvalerate-treated explants or the DMSO control
(Fig. 5A). In all explants tested, expression of total Jun was
maintained. Interestingly, pAkt expression levels were increased
in the okadaic acid- and Fostriecin-treated explants (Fig. 5B),
consistent with a known role for Pp2a in the dephosphorylation
of Akt (Ugi et al., 2004) and validating the specificity and activity
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Fig. 3. Co-imaging of the barrier front and protein expression
shows that barrier acquisition occurs within the pulse of
suprabasal Akt activation and just before the pulse of Jun
dephosphorylation. (A) Serial sections comparing the barrier front
(arrowhead) in a Hematoxylin-stained mouse fetus with expression of
pJun. 1, 2 and 3 correspond to the respective inset figures. The pJun
figure is a composite image, allowing for better imaging of pJun at the
same scale. Small arrowheads in the insets indicate examples of pJun
expression in the upper granular layer. (B) Comparison of pAkt
expression with the barrier front (arrowhead) in epidermis from a
Hematoxylin-stained mouse fetus, with positions 1, 2 and 3 shown as
insets. The dashed lines in A and B indicate the dermal-epidermal
boundary. Note that the barrier front is moving from right to left in this
figure. Scale bars: 100μm.
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of the Pp2a inhibitors in this experiment. pAkt expression levels
in the fenvalerate-treated explants was comparable to that in the
controls.
We tested the treated explants for barrier function by Toluidine
Blue exclusion (Fig. 5C). Both the okadaic acid- and Fostriecin-
treated explants had defective barrier function to a lesser degree
compared with the DMSO control. Fenvalerate-treated explants
also allowed penetration of Toluidine Blue, although to a lesser
degree than those treated with the Pp2a inhibitors. These data
show that both the developmental downregulation of Jun
phosphorylation and barrier formation could be mediated by Pp2a
activity.
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Fig. 4. Dephosphorylation of Jun and epidermal barrier
function are Akt dependent. (A) Immunohistochemical
analysis of embryonic explants treated with 100μM SH-5 or
vehicle (DMSO). Inhibition of Akt by SH-5 was effective,
reducing levels of pAkt and expression of the downstream Akt
target pmTOR. Loricrin expression was maintained in both
explants, showing that the overall differentiation program
remained unchanged. However, inhibition of Akt by SH-5
resulted in maintenance of Jun phosphorylation; note that Jun
phosphorylation is developmentally downregulated, as
expected, in the DMSO-treated control. (B) Surface view of
epidermal explants after Toluidine Blue dye penetration assay.
The DMSO-treated control was resistant to dye penetration,
indicating barrier acquisition, whereas explants treated with
SH5 had impaired barrier function. Arrowheads indicate
examples of nuclear expression of Jun and pJun in the granular
layer. The dashed lines indicate the dermal-epidermal junction.
Scale bar: 50μm.
Fig. 5. Dephosphorylation of Jun and epidermal
barrier function are Pp2a dependent.
(A) Immunohistochemical analysis of pJun and Jun in
embryonic explants treated with the Pp2a inhibitors
okadaic acid (10 nM), Fostriecin (20μM) and
fenvalerate (20μM). Phosphorylation of Jun was
maintained in explants in which Pp2a, but not Pp2b,
was inhibited. Vertical arrowheads indicate nuclear Jun
and pJun in the granular layer. (B) Immunofluorescence
analysis of pAkt expression in treated explants.
Expression was increased in explants treated with the
Pp2a inhibitors. (C) Toluidine Blue dye penetration assay
on explants treated with okadaic acid, Fostriecin or
fenvalerate. Barrier function was impaired when Pp2a
was inhibited, and to a lesser extent when Pp2b was
inhibited. Dashed lines indicate the dermal-epidermal
junction. Scale bars: 50μm.
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Expression of Ppp2r2a is affected by Akt activity
Recent data functionally link the Ppp2r2 family members to Akt
(Kuo et al., 2008). We performed RT-PCR analysis of E15.5-18.5
skin and determined that Ppp2r2a was the most highly expressed
family member during barrier acquisition, with expression of
Ppp2r2a message peaking at E16.5 (see Fig. S2 in the
supplementary material). Immunofluorescence showed increased
expression of Ppp2r2a in E17.5 fetal skin (Fig. 6A) and
expression in the nuclei of cultured keratinocytes, which
coexpress Jun (Fig. 6B), Hence, Ppp2r2a could potentially be the
regulatory subunit of Pp2a that targets Jun during barrier
formation.
Expression of epidermal Ppp2r2a was markedly reduced in SH-
5 treated explants (Fig. 6C), implying that its expression levels
were indeed regulated by Akt signaling. The expression of the
catalytic subunit of Pp2a, Pp2ac, was unchanged in the SH-5
treated explants, showing that the regulatory subunit expression
was specifically affected by Akt signaling. Immunoprecipitation
of a rat epidermal keratinocyte lysate with a Jun-specific antibody,
unlike the isotype control, was able to pull down Ppp2r2a
(Fig. 6D), suggesting a physical interaction between the two
proteins.
Ppp2r2a is necessary for both the
dephosphorylation of Jun and for the rapid
acquisition of barrier function in an organotypic
culture model
We transfected rat epidermal keratinocytes with two different
shRNA plasmid constructs in order to downregulate the expression
of Ppp2r2a by siRNA. The second construct (Ppp2r2a siRNA2)
knocked down expression of Ppp2r2a by around 90% in western
blots compared with levels in cells transfected with a scrambled
oligonucleotide control (scram, Fig. 7A). Expression of Ppp2r2a
was markedly reduced in siRNA2-expressing cells compared with
scrambled controls (Fig. 7B).
Ppp2r2a knockdown perturbed stratum corneum homeostasis,
consistent with barrier dysfunction. Hyperkeratosis was observed in
the siRNA-expressing cultures, diagnostic of barrier perturbation,
and there were associated changes in the program of terminal
differentiation, with a marked increase in both loricrin and
involucrin expression, whereas expression of keratin 10 appeared
unchanged (Fig. 7C).
Reducing Ppp2r2a expression led to substantially increased Jun
phosphorylation, suggesting that Ppp2r2a is a regulatory subunit
responsible for the dephosphorylation of Jun (Fig. 7D). In the
Ppp2r2a siRNA cultures, pAkt expression was unchanged (not
shown).
To link the changes in Jun phosphorylation to developmental
barrier acquisition, rat epidermal keratinocyte organotypic cultures
were grown on de-epidermized dermis at the air-liquid interface for
5 and 10 days (Baden and Kubilus, 1983; Marjukka et al., 2003;
O’Shaughnessy et al., 2007b) to assay differences in initial barrier
acquisition. Ppp2r2a siRNA and scrambled control cultures were
also treated with the JNK inhibitor SP600125 or vehicle, to test
whether inhibiting Jun phosphorylation could restore normal barrier
acquisition characteristics. Barrier function was assayed by staining
the organotypic cultures whole mount with Hematoxylin then
sectioning (Materials and methods) (see Fig. 3). In this assay,
barrier-incompetent organotypic cultures will allow Hematoxylin
to penetrate, staining the nuclei of the epidermis blue. The
scrambled oligonucleotide controls were barrier competent at day
5, whereas the barrier was still defective at day 5 in the siRNA-
expressing cultures (Fig. 8A,B). Histological analysis of the culture
indicated that the epidermis of the scrambled cultures gradually
acquired a cornified layer, whereas from day 5 onwards the siRNA-
expressing cultures were hyperkeratotic, showing an increasingly
thickened cornified layer at days 5 and 10 (Fig. 8C). The siRNA-
expressing culture also showed retention of pJun staining as
expected (Fig. 8D). Therefore the knockdown of Ppp2r2a
expression caused a defect during epidermal barrier development
in culture, which is apparently only ameliorated when the cornified
layer is thickened.
Treatment of the cultures with the JNK inhibitor SP600125 had
no effect on barrier acquisition in the scrambled siRNA control (data
not shown). However, strikingly, barrier acquisition in SP600125-
treated siRNA cultures appeared restored to that found in the
scrambled control culture (Fig. 8B-D), providing further evidence
that Ppp2r2a acts through Jun dephosphorylation to bring about
barrier acquisition.
DISCUSSION
We report here that epidermal barrier acquisition in late embryonic
development is accompanied by a pulse of Akt activation and a
transient decrease in Jun phosphorylation. Experimental inhibition
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Fig. 6. Ppp2r2a expression is Akt dependent and
increases after barrier formation. Ppp2r2a co-localizes
with, and can bind, Jun. (A) Immunofluorescence analysis
for Ppp2r2a of frozen sections of E16.5 and E17.5 dorsal
skin, corresponding to timepoints pre- and post-barrier
acquisition. (B) Co-immunofluorescence analysis of Ppp2r2a
and Jun in rat epidermal keratinocytes showing widespread
co-localization. (C) Co-immunofluorescence analysis of frozen
sections from drug- and vehicle-treated epidermal explants
for the expression of Ppp2r2a and Pp2ac. Note that although
the expression of Ppp2r2a decreased in the SH5-treated
explants, the expression of Pp2ac was unchanged. Analysis
of pAkt confirms that the SH-5 has inhibited Akt.
(D) Immunoprecipitation (IP) western of rat keratinocyte
lysate pulled down with an anti-Jun antibody or with an anti-
Ppp2r2a antibody and with a respective control isotype (IgG)
antibody. Scale bars: 50μm in A,C; 10μm in B.
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of Akt signaling in a developing epidermal model reduces Jun
dephosphorylation and prevents barrier acquisition, suggesting that
this ‘pulse’ of cessation of Jun phosphorylation is downstream of
Akt signaling and is necessary for barrier formation. We used
inhibitor studies in the same developing epidermal model to show
that dephosphorylation of Jun is mediated by Pp2a, and that
expression of a Pp2a regulatory subunit, Ppp2r2a, is regulated by
Akt. Hence, we propose that the developmental pulse of Akt activity
upregulates Pp2a via Ppp2r2a, causing dephosphorylation of Jun
and barrier acquisition (Fig. 9). In support of this proposal we show
that reduction of Ppp2r2a expression by siRNA significantly
increases phosphorylation of Jun and interferes with epidermal
barrier formation, and inhibition of Jun phosphorylation restores
barrier function even in the absence of Ppp2r2a.
There are clear links between Akt function and barrier acquisition.
In the Akt1; Akt2 double null mouse, barrier function is severely
affected, leading to perinatal lethality (Peng et al., 2003), whereas
we have reported that mice null for Akt1 have a mild barrier
dysfunction in adulthood (O’Shaughnessy et al., 2007b). Epidermal-
specific Pten knockouts, which exhibit hyperactivation of Akt, show
postnatal hyperplasia and hyperkeratosis (Suzuki et al., 2003;
Backman et al., 2004). Barrier acceleration was not reported in these
animals, although this may be because Akt activity during
embryogenesis is already above the threshold to induce barrier
function.
One of the most striking observations was the transient
dephosphorylation of Jun at the barrier front. Little is known about
epidermal Jun and its role in barrier acquisition and homeostasis.
Wound healing is one situation in which Jun expression is
upregulated (Yates and Rayner, 2002) and barrier function is
reduced to facilitate the closing of the wound by increasing the
migration of the keratinocytes at the wound margin. However, Jun
expression is reduced in psoriasis, a hyperproliferative and
hyperkeratotic disorder that is associated with a barrier dysfunction
(Basset-Seguin et al., 1991), and a psoriasis-like disease was
observed in mice with an inducible knockdown of Jun and JunB
(Zenz et al., 2005). This suggests that the roles of Jun during normal
homeostasis and pathology are different.
There are several reports showing that either pharmacologic
inhibition of the PI3 kinase pathway or activation of AKT signaling
reduced Jun phosphorylation in diverse human cell lines (Levresse
et al., 2000; Suhara et al., 2002; Song and Lee, 2005). However,
recent data indicates that PTEN null cells, although they have
increased AKT phosphorylation, exhibit higher levels of JUN
phosphorylation (Vivanco et al., 2007). Therefore, the relationship
between AKT signaling and JUN phosphorylation could be context
dependent.
Pp2a has a role in Jun dephosphorylation and barrier formation
downstream of Akt. However, Pp2a can act as a phosphatase
upstream of Akt (Yamada et al., 2001; Ugi et al., 2004; Gao et al.,
2005), and this suggests a mechanism whereby the developmental
pulse of Akt could occur. However, although Pp2a inhibition
increased Akt serine phosphorylation, Ppp2r2a knockdown had
no effect on Akt serine phosphorylation. This is because inhibitors
target the range of Pp2a holoenzymes, whereas the siRNA is
specific for the Ppp2r2a regulatory subunit. Therefore, it is
plausible that Ppp2r2a is downstream of Akt and that another
Pp2a regulatory subunit controls the subsequent downregulation
of Akt. This is consistent with findings in Caenorhabditis
elegans, in which B56β and not B55α (Ppp2r2a) is responsible
for dephosphorylation of AKT-1 at the equivalent serine
(Padmanabhan et al., 2009).
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Fig. 7. siRNA knockdown of Ppp2r2a maintains Jun
phosphorylation and causes defects in terminal
differentiation. (A) Western blot analysis of two lines of
rat epidermal keratinocytes (REKs) expressing different
Ppp2r2a shRNA-containing plasmids and one expressing
a scrambled control for Ppp2r2a, with actin as a loading
control. siRNA2 caused substantial knockdown of
Ppp2r2a. (B) Immunofluorescence analysis of Ppp2r2a in
the scrambled line and siRNA2 line, confirming
substantial knockdown. (C) Immunohistochemical
analysis of keratin 10, involucrin and loricin in the same
organotypic cultures. (D) Immunohistochemical analysis
of pJun and Jun in the scrambled control and siRNA-
expressing organotypic cultures. Scale bars: 50μm.
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Ppp2r2a knockdown leads to hyperphosphorylation of Jun, and
Ppp2r2a and Jun bind in immunoprecipitation assays, providing
evidence that Pp2a holoenzymes containing this regulatory subunit
can directly target Jun, in agreement with reports that Pp2a interacts
with Jun in bacterial two-hybrid assays (Avdi et al., 2002; Zhao et
al., 2008).
Both Pp2a inhibition and Ppp2r2a knockdown led to gross barrier
dysfunction, as shown by dye-penetration assays. The only well-
characterized function for Pp2a in epidermis is filaggrin
dephosphorylation (Kam et al., 1993). Also protein-protein
interactions between filaggrin and Hsp27 are necessary for correct
cornified layer formation and corneocyte assembly (O’Shaughnessy
et al., 2007b), whereas filaggrin mutations are associated with
ichthyosis vulgaris, a common barrier dysfunction disorder (Smith
et al., 2006). This clearly shows an association, at least via filaggrin,
between Pp2a and barrier function. We are proposing here that Pp2a
also has important multiple roles in the acquisition of barrier
function, including the dephosphorylation of Jun. Further research
is warranted on the multiple functions of Pp2a holoenzymes in the
epidermis.
In Ppp2r2a knockdown cultures, barrier function is rescued
concomitant with premature hyperkeratosis (a thickening of the
cornified layers). It is possible, therefore, that the sheer thickness of
the cornified layer confers barrier function. This suggests two key
ideas. Firstly that initial barrier acquisition precedes the formation of
the mature cornified layer in the organotypic model, consistent with
observations in mice that barrier acquisition precedes the formation
of the mature cornified layer (Hardman et al., 1998). Secondly, these
data suggest that hyperkeratosis occurs in response to impaired
barrier and is therefore a secondary effect. This is in agreement with
the widely held concept that hyperkeratosis is a universal response to
barrier impairment (Williams and Elias, 2003). This would also be
consistent with the grafting of transglutaminase 1 null epidermis on
nude mice, in which the initial barrier defect in the epidermis is
counteracted by hyperkeratosis (Kuramoto et al., 2002).
To conclude, we provide evidence establishing an important role
for Akt signaling in the initial acquisition of epidermal barrier
function, consistent with known roles of Akt in epidermal barrier
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Fig. 8. siRNA knockdown of Ppp2r2a causes a
transient barrier defect and hyperkeratosis in
organotypic culture, which is restored by JNK
inhibition. (A) Hematoxylin barrier assay of organotypic
cultures expressing the Ppp2r2a siRNA and scrambled
control, grown for 3, 5 and 10 days at the air-liquid
interface. Blue nuclei indicate defective barrier function in
the siRNA organotypic culture at 3 and 5 days.
(B) Hematoxylin barrier assay of organotypic cultures
expressing the Ppp2r2a siRNA and scrambled control and
the Ppp2r2a siRNA-expressing culture grown in 50 nM
SP600125 for 5 and 10 days at the air-liquid interface.
(C) Hematoxylin and Eosin staining of the scrambled,
siRNA-expressing and SP600125-treated siRNA-
expressing cultures showing the hyperkeratotic response
in the siRNA-expressing cultures, which is abrogated by
addition of the JNK inhibitor SP600125. (D) pJun
expression in each of the cultures, confirming reduction
of Jun phosphorylation in siRNA-expressing cultures
treated with SP600125. Dashed lines indicate the dermal-
epidermal junction. Scale bars: 50μm.
Fig. 9. A model of the mechanism of Jun dephosphorylation by
Akt-mediated Pp2a function. Akt activity causes upregulation of
Ppp2r2a expression. Inhibition of Akt activity reduces Ppp2r2a expression
and leads to barrier defects. Ppp2r2a then forms part of the Pp2a
holoenzyme that specifically targets Jun for dephosphorylation, leading to
barrier acquisition. Consistent with this, both siRNA knockdown of
Ppp2r2a and inhibition of Pp2a activity lead to barrier defects. D
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function (Peng et al., 2003; O’Shaughnessy et al., 2007b). The
discovery of Akt regulation of Ppp2r2a expression and the
subsequent control of Jun phosphorylation is yet another important
function for Akt signaling in epidermis.
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